Boehringer Ingelheim has upgraded to the latest version of InnovoCommerce's innovoPOINT.
BioClinica has expanded the range of ways customers can access its suite of eClinical tools. The new service, dubbed the BioClinica eHealth Cloud, allows biopharma companies and CROs to run Express EDC, Trident RTSM and other pieces of trial software on public, private, managed or custom cloud infrastructure.
The move marks the first time a study run using the ResearchKit platform--which made a splash earlier this year when it facilitated rapid enrollment in a handful of trials--has started accepting participants from outside the U.S.
Illumina has struck a deal to acquire laboratory information management system player GenoLogics Life Sciences Software, ending years of speculation about the sequencing giant's interest in the business.
PRA plans to integrate the acquired assets into its nascent Predictivv platform and in doing so continue its attempts to use IT to stand out from the CRO crowd.
GlaxoSmithKline has revealed it is working to integrate Apple's ResearchKit into its clinical trials, setting it up to be one of the first drug developers to adopt the recently introduced platform. The Big Pharma sees the open-source research app as a useful tool for data collection.
A team at the University of California, San Diego (UCSD), has found biomarkers for ovarian tumors by mining two National Institutes of Health-sponsored databases. The bioinformatics-enabled research program has raised expectations that earlier diagnoses of ovarian cancer can be made, an advance that could improve outcomes in a tough therapeutic indication.
Medidata has connected its Clinical Cloud to Apple's ResearchKit. The link means researchers can feed data gathered by ResearchKit apps into Medidata's cloud platform, where the information can be integrated with other sources of clinical trial results.
Legislation that would mandate the creation of a system to share de-identified clinical trial data has moved a step closer to coming into force. The text is included in the latest draft of the 21st Century Cures Act, which is almost 200 pages shorter than the original proposal.
Eli Lilly, Novartis and Pfizer have found a new home for the tech they created to improve ClinicalTrials.gov. The group is giving what it has achieved to date to TrialReach, a tech company developing a patient-focused clinical trial discovery platform.